Healing & repair
TB-500
Full-length thymosin beta-4 has been studied in early-phase human trials for dry eye and wound healing, but TB-500 itself is supported almost entirely by animal and in-vitro data.
Also known as Thymosin Beta-4 fragment · TB4 Frag 17-23 · Tβ4
ANIMAL DATA ONLY
The evidence is animal and cell-culture work. There are no controlled human dosing trials, so every number below is convention rather than a result.
Full-length thymosin beta-4 reached early human trials; TB-500 itself is supported almost entirely by animal and in-vitro data. Banned by WADA.
At a glance
Dose summary
No regulator and no trial set these numbers. They describe what people actually do, recorded so you can see the range rather than guess at it — which is not the same thing as a recommendation.
Reconstitution
What to draw, at the usual vial
A 2 mg vial reconstituted with 2 mL of bacteriostatic water gives 1.00 mg/mL. A typical 300 mcg dose is 0.300 mL — pull the plunger to 30 units on a U-100 syringe.
Same dose, other vial sizes
| Vial | Water | Concentration | Draw | Units | Doses |
|---|---|---|---|---|---|
| 2 mg | 2 mL | 1.00 mg/mL | 0.300 mL | 30 units | 6 |
| 5 mg | 2 mL | 2.50 mg/mL | 0.120 mL | 12 units | 16 |
| 10 mg | 2 mL | 5.00 mg/mL | 0.060 mL | 6 units | 33 |
The highlighted row is the one quoted above: the smallest listed vial that holds at least four typical doses. Change any of it — a different vial, more or less water, a different dose — on the reconstitution calculator, which draws the syringe to true U-100 graduations.
Mechanism & evidence
What it is, and what is known
Full-length thymosin beta-4 has been studied in early-phase human trials for dry eye and wound healing, but TB-500 itself is supported almost entirely by animal and in-vitro data. It is not an approved medicine and is banned by WADA. The dosing here is the 200-500 mcg daily convention that vendor and practitioner guides converge on, with maintenance around 150-200 mcg three to five times a week. The older loading convention of 2-5 mg twice weekly for 4-6 weeks also circulates; the weekly totals are closer than the per-dose figures make them look.
Tolerability
Reported side effects
- Injection site irritation or redness
- Transient head rush or fatigue after dosing
- Temporary lethargy in the first week
Hard stops
Do not use this if
- Pregnancy, possible pregnancy, or breastfeeding
- Active, suspected or recently treated malignancy
These are flags, not a screening. They do not replace a conversation with a clinician who knows your history.
Handling
Storage
Keep it cold, keep it dark, and label the vial with the date you mixed it. Discard anything cloudy or past the window above.
Combinations
Commonly stacked with
Stacking multiplies the side-effect surface and makes it impossible to tell which compound did what. Add one thing at a time.
Where it shows up
Protocols using this compound
References
Sources
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.